DE69942837D1 - Systemisches virus/ligand genabgabemittel und gentherapie - Google Patents
Systemisches virus/ligand genabgabemittel und gentherapieInfo
- Publication number
- DE69942837D1 DE69942837D1 DE69942837T DE69942837T DE69942837D1 DE 69942837 D1 DE69942837 D1 DE 69942837D1 DE 69942837 T DE69942837 T DE 69942837T DE 69942837 T DE69942837 T DE 69942837T DE 69942837 D1 DE69942837 D1 DE 69942837D1
- Authority
- DE
- Germany
- Prior art keywords
- virus
- ligand
- gene therapy
- geneaving
- interest
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700605 Viruses Species 0.000 title abstract 7
- 239000003446 ligand Substances 0.000 title abstract 5
- 238000001415 gene therapy Methods 0.000 title abstract 2
- 230000009885 systemic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 239000004971 Cross linker Substances 0.000 abstract 1
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108090000901 Transferrin Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003431 cross linking reagent Substances 0.000 abstract 1
- -1 e.g. Substances 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10923698P | 1998-11-19 | 1998-11-19 | |
| US12833099P | 1999-04-08 | 1999-04-08 | |
| PCT/US1999/027365 WO2000029600A1 (en) | 1998-11-19 | 1999-11-19 | Systemic viral/ligand gene delivery system and gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69942837D1 true DE69942837D1 (de) | 2010-11-18 |
Family
ID=26806780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69942837T Expired - Lifetime DE69942837D1 (de) | 1998-11-19 | 1999-11-19 | Systemisches virus/ligand genabgabemittel und gentherapie |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1131457B1 (de) |
| JP (2) | JP5448283B2 (de) |
| CN (1) | CN100572542C (de) |
| AT (1) | ATE483816T1 (de) |
| AU (1) | AU1628800A (de) |
| CA (1) | CA2349238A1 (de) |
| DE (1) | DE69942837D1 (de) |
| HK (1) | HK1041498B (de) |
| PT (1) | PT1131457E (de) |
| WO (1) | WO2000029600A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10337770A1 (de) * | 2003-08-14 | 2005-03-24 | TransMIT Gesellschaft für Technologietransfer mbH | Endothelzellspezifisches Gentransfersystem |
| NZ724348A (en) | 2010-11-30 | 2019-12-20 | Genentech Inc | Low affinity blood brain barrier receptor antibodies and uses therefor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US5378457A (en) | 1981-12-24 | 1995-01-03 | Virogenetics Corporation | Interferon sensitive recombinant poxvirus vaccine |
| US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| JPH07500961A (ja) | 1990-10-01 | 1995-02-02 | ユニバーシティ オブ コネチカット | 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定 |
| KR100242671B1 (ko) | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
| US5521291A (en) | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
| NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| DE4311651A1 (de) * | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen |
| AU2112697A (en) * | 1996-02-09 | 1997-08-28 | Pi-Wan Cheng | Receptor ligand-facilitated delivery of biologically active molecules |
| AU2678097A (en) * | 1996-04-16 | 1997-11-07 | Immusol Incorporated | Targeted viral vectors |
| JP2001515493A (ja) | 1997-03-14 | 2001-09-18 | セレクティブ ジェネティックス，インコーポレイテッド | 改変された親和性を有するアデノウイルスベクター |
-
1999
- 1999-11-19 AU AU16288/00A patent/AU1628800A/en not_active Abandoned
- 1999-11-19 DE DE69942837T patent/DE69942837D1/de not_active Expired - Lifetime
- 1999-11-19 AT AT99959034T patent/ATE483816T1/de active
- 1999-11-19 EP EP99959034A patent/EP1131457B1/de not_active Expired - Lifetime
- 1999-11-19 CA CA002349238A patent/CA2349238A1/en not_active Abandoned
- 1999-11-19 WO PCT/US1999/027365 patent/WO2000029600A1/en active Application Filing
- 1999-11-19 JP JP2000582581A patent/JP5448283B2/ja not_active Expired - Fee Related
- 1999-11-19 PT PT99959034T patent/PT1131457E/pt unknown
- 1999-11-19 CN CNB998135054A patent/CN100572542C/zh not_active Expired - Fee Related
-
2002
- 2002-03-11 HK HK02101830.0A patent/HK1041498B/zh not_active IP Right Cessation
-
2010
- 2010-07-08 JP JP2010155986A patent/JP2010213726A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002530086A (ja) | 2002-09-17 |
| ATE483816T1 (de) | 2010-10-15 |
| WO2000029600A1 (en) | 2000-05-25 |
| EP1131457A1 (de) | 2001-09-12 |
| JP2010213726A (ja) | 2010-09-30 |
| CN1326511A (zh) | 2001-12-12 |
| PT1131457E (pt) | 2010-11-18 |
| CN100572542C (zh) | 2009-12-23 |
| HK1041498A1 (en) | 2002-07-12 |
| AU1628800A (en) | 2000-06-05 |
| EP1131457B1 (de) | 2010-10-06 |
| CA2349238A1 (en) | 2000-05-25 |
| JP5448283B2 (ja) | 2014-03-19 |
| HK1041498B (zh) | 2011-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002305450A1 (en) | Proteomimetic compounds and methods | |
| NO20013701D0 (no) | HER-2/neu-fusjonsproteiner | |
| CY1114265T1 (el) | Πρωτεϊνη συντηξης αλβουμινης | |
| TR199701071T2 (xx) | Aktif madde ulaştırmaya mahsus bileşikler ve terkipler. | |
| ATE200105T1 (de) | Verfahren und zusammensetzungen als vehikel zur zielgerichtete einbringen von genen | |
| ATE279430T1 (de) | Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen | |
| ATE368054T1 (de) | Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität | |
| ATE383169T1 (de) | Komponente und zusammensetzungen zur verabreichung von wirkstoffen | |
| WO2002012341A3 (en) | Her-2/neu fusion proteins | |
| BR0108959A (pt) | Composições de poloxmero ou poloxamina melhoradas para distribuição de ácido nucléico | |
| ATE382697T1 (de) | Mutierte version der arginin deiminase | |
| CY1107431T1 (el) | Σωματιδια για γoνιδιακη θεραπεια | |
| AR042968A1 (es) | Anticuerpos de virus anti-dengue composiciones metodos y usos | |
| ATE385517T1 (de) | Interferon ähnliche moleküle, und deren verwendungen | |
| FR2857267B1 (fr) | Formulation stabilisante et solubilisante pour les proteines cryoprecipitables. | |
| DE69942837D1 (de) | Systemisches virus/ligand genabgabemittel und gentherapie | |
| TR200100430T2 (tr) | Tyrosine kinase SRC kullanılan angiogenesisin modülasyonu için yararlı metot ve bileşimler. | |
| PT866861E (pt) | Clonagem molecular e caracterizacao de moleculas relacionadas com relaxina e com a familia dos ligandos da insulina | |
| DE60131975D1 (de) | Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten | |
| BR0013228A (pt) | Método e composições utilizados para modulação de angiogenese usando proteìna quinase raf e ras | |
| WO2002062964A3 (en) | Ap1 amine oxidase variants | |
| TW200517125A (en) | Pharmaceutical composition for treatment of solid cancers | |
| ATE528392T1 (de) | Neues protein und dessen dns | |
| Zhou et al. | Research on PEGylation of porcine prothrombin for improving biostability and reducing animal immunogenicity | |
| TR200002611T2 (tr) | Beta-lipotropin ve kullanımları |